EDMA

EDMA

Systematic (IUPAC) name
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine
Clinical data
Routes of administration	Oral
Legal status	Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Identifiers
ATC code	None
PubChem	CID 24257269
ChemSpider	23553090 Y
Chemical data
Formula	C12H17NO2
Molar mass	207.269 g/mol
SMILES CC(Cc1ccc2c(c1)OCCO2)NC
InChI InChI=1S/C12H17NO2/c1-9(13-2)7-10-3-4-11-12(8-10)15-6-5-14-11/h3-4,8-9,13H,5-7H2,1-2H3 Y Key:UJKWLAZYSLJTKA-UHFFFAOYSA-N Y
(verify)

This article is about the amphetamine. For other uses, see EDMA (disambiguation).

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the amphetamine class. It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring. EDMA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours. According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects. Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release. Based on Shulgin's reports of essential inactivity at 150–250 mg, it may be more active at higher doses.

See also

• Ethylidenedioxyamphetamine
• Tetralinylaminopropane
• Naphthylaminopropane

External links

• EDMA entry in PiHKAL
• MDMC (EDMA) entry in PiHKAL • info